Restoring glucose metabolism: a new approach to reversing cognitive decline in AD

Andreasson, Katrin

We noted you are experiencing viewing problems

Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems.
No luck yet? More tips for troubleshooting viewing issues
Contact HST Support access@hstalks.com

Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
For additional help, please don't hesitate to contact HST support access@hstalks.com

We hope you have enjoyed this limited-length demo

Request free trial
Recommend to your librarian

Share
Share This Talk
Messaging

Outlook

Gmail

Yahoo!

WhatsApp
Social

Facebook

X

LinkedIn

VKontakte
Permalink
Replay Talk

This is a limited length demo talk; you may login or review methods of obtaining more access.

Topics
Biography
Links
Citation

Topics Covered

Neurogenerative disorders
Alzheimer’s disease pathologies
Glucose metabolism
Preclinical models
Astrocytic IDO1

Biography

Katrin Andreasson is a professor in the Department of Neurology and Neurological Sciences at Stanford University School of Medicine and is a physician-scientist with a longstanding commitment to understanding preclinical mechanisms leading to the development of Alzheimer’s disease (AD). Dr. Andreasson cares for patients with dementia in the Stanford Memory Disorders Clinic and carries out basic preclinical research in mouse models of neurodegeneration. A principal focus of Dr. Andreasson’s research has been the investigation of cellular and molecular mechanisms of brain injury mediated by cyclooxygenase and its downstream prostaglandin receptor pathways. The COX/PGE2 pathway has been implicated in brain injury in a broad spectrum of neurological diseases, including AD, where epidemiologic studies indicate a preventive effect of NSAIDs in cognitively normal aging human populations. Dr. Andreasson’s laboratory has identified harmful PGE2 receptors that contribute to AD-like pathology in AD model mice, and these findings are helping to drive efforts to develop antagonists to PGE2 receptors for the prevention of AD. More recently, experiments modeling the preventive effects of NSAIDs in AD model mice have led to the hypothesis that increased tryptophan metabolism may contribute to early neuronal and later inflammatory pathology in AD.

Links

Talk Citation

Andreasson, K. (2025, February 27). Restoring glucose metabolism: a new approach to reversing cognitive decline in AD [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 9, 2025, from https://doi.org/10.69645/SHCV5144.
Export Citation (RIS)